{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:53:51Z","timestamp":1791312831424,"version":"4.3.1"},"reference-count":21,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2015,7,29]],"date-time":"2015-07-29T00:00:00Z","timestamp":1438128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"The Association Oligocyte"},{"name":"The Association pour le d\u00e9veloppement des neurosciences \u00e0 Avicenne (ADNA)"},{"name":"The Assistance Publique - H\u00f4pitaux de Paris"},{"name":"Oligovax Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2015,9]]},"abstract":"<jats:p><jats:styled-content style=\"fixed-case\">TLR<\/jats:styled-content>\u20109 agonists are immunostimulating agents that have antitumor effects in animal models. A phase I trial was conducted to define the safety profile of subcutaneous injections, combined with intrathecally administration of CpG\u201028, a <jats:styled-content style=\"fixed-case\">TRL<\/jats:styled-content> 9 agonist, in patients with neoplastic meningitis (<jats:styled-content style=\"fixed-case\">NM<\/jats:styled-content>). Cohorts of 3\u20136 patients with <jats:styled-content style=\"fixed-case\">NM<\/jats:styled-content> were treated for 5\u00a0weeks with escalating doses of CpG\u201028. The primary endpoint was tolerance. Secondary endpoints were progression free survival (<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>) and overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>). Twenty\u2010nine patients were treated with CpG\u201028. The primary cancers were malignant glioma, lung carcinoma, breast cancer, melanoma or melanocytoma, ependymoma, and colorectal cancer. The median age was 56\u00a0years and median Karnovsky Performance status (KPS) was 70%. The treatment was well tolerated. Adverse effects that were possibly or probably related to the studied drug were grade 2 lymphopenia, anemia and neutropenia, local erythema at injection sites, fever and seizure. There were five serious adverse events: two confusions, two infections of ventricular devices and one grade 4 thrombopenia and neutropenia. The median <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> was 7\u00a0weeks and median <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> was 15\u00a0weeks. Interestingly, the median survival was slightly (but not significantly) higher in the eight patients who were concomitantly treated with bevacizumab (19\u00a0weeks <jats:italic>vs<\/jats:italic> 15\u00a0weeks; <jats:italic>P\u00a0=\u00a0<\/jats:italic>0.11). CpG\u201028 was well tolerated at doses up to 0.3\u00a0mg\/kg subcutaneously and 18\u00a0mg intrathecally. Additional trials are warranted.<\/jats:p>","DOI":"10.1111\/cas.12724","type":"journal-article","created":{"date-parts":[[2015,6,19]],"date-time":"2015-06-19T09:52:53Z","timestamp":1434707573000},"page":"1212-1218","source":"Crossref","is-referenced-by-count":30,"title":["Immunotherapy with CpG\u2010<scp>ODN<\/scp> in neoplastic meningitis: A phase I trial"],"prefix":"10.1111","volume":"106","author":[{"given":"Renata","family":"Ursu","sequence":"first","affiliation":[{"name":"Department of Neurology H\u00f4pital Avicenne Bobigny France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Taillibert","sequence":"additional","affiliation":[{"name":"Department of Neurology Mazarin H\u00f4pital Piti\u00e9\u2010Salp\u00eatri\u00e8re University Pierre et Marie Curie Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Banissi","sequence":"additional","affiliation":[{"name":"Department of Neurology H\u00f4pital Avicenne Bobigny France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Vicaut","sequence":"additional","affiliation":[{"name":"Methodology and Statistical Unit Centre Hospitalier Universitaire Lariboisi\u00e8re Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bailon","sequence":"additional","affiliation":[{"name":"Department of Neurology H\u00f4pital Avicenne Bobigny France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Le Rhun","sequence":"additional","affiliation":[{"name":"Breast Unit Department of Medical Oncology Oscar Lambert Center Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Sebastien","family":"Guillamo","sequence":"additional","affiliation":[{"name":"Department of Neurology H\u00f4pital C\u00f4te\u2010de\u2010Nacre CHU de Caen Caen Cedex France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Psimaras","sequence":"additional","affiliation":[{"name":"Department of Neurology Mazarin H\u00f4pital Piti\u00e9\u2010Salp\u00eatri\u00e8re University Pierre et Marie Curie Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick","family":"Tibi","sequence":"additional","affiliation":[{"name":"Agence G\u00e9n\u00e9rale des Equipements et Produits de Sant\u00e9 (AGEPS) Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adama","family":"Sacko","sequence":"additional","affiliation":[{"name":"Department of Neurology H\u00f4pital Avicenne Bobigny France"},{"name":"UFR de Sant\u00e9, M\u00e9decine et Biologie Humaine de Bobigny \u2013 Universit\u00e9 Paris 13 Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athina","family":"Marantidou","sequence":"additional","affiliation":[{"name":"Department of Neurology H\u00f4pital Avicenne Bobigny France"},{"name":"UFR de Sant\u00e9, M\u00e9decine et Biologie Humaine de Bobigny \u2013 Universit\u00e9 Paris 13 Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Belin","sequence":"additional","affiliation":[{"name":"Department of Neurology H\u00f4pital Avicenne Bobigny France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine F.","family":"Carpentier","sequence":"additional","affiliation":[{"name":"Department of Neurology H\u00f4pital Avicenne Bobigny France"},{"name":"UFR de Sant\u00e9, M\u00e9decine et Biologie Humaine de Bobigny \u2013 Universit\u00e9 Paris 13 Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,7,29]]},"reference":[{"issue":"4","key":"e_1_2_7_2_1","first-page":"S265","article-title":"Carcinomatous meningitis: leptomeningeal metastasis in solid tumors","volume":"4","author":"Le Rhun E","year":"2013","journal-title":"Surg Neurol Int"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200411000-00006"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-200110080-00010"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/124.3.480"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-415"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-008-9536-2"},{"key":"e_1_2_7_8_1","first-page":"5429","article-title":"Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice","volume":"59","author":"Carpentier AF","year":"1999","journal-title":"Cancer Res"},{"key":"e_1_2_7_9_1","first-page":"2469","article-title":"Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs","volume":"6","author":"Carpentier AF","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1215\/S1522851705000475"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nop047"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.10.3110"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9129"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318174a4df"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000211304.60126.8f"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-3146-6_8"},{"key":"e_1_2_7_17_1","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1177\/135965350701200501","article-title":"Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll\u2010like receptor 9 agonist","volume":"12","author":"Vicari AP","year":"2007","journal-title":"Antivir Ther"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24473"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2009.01361.x"},{"key":"e_1_2_7_20_1","first-page":"iii85","article-title":"A pilot study of systemically administered bevacizumab in patients with neoplastic meningitis\/imaging, clinical, CSF, and biomarker outcomes","volume":"13","author":"Groves MD","year":"2011","journal-title":"Neuro Oncol"},{"key":"e_1_2_7_21_1","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1158\/0008-5472.CAN-12-2325","article-title":"VEGFA\u2010VEGFR pathway blockade inhibits tumor\u2010induced regulatory T\u2010cell proliferation in colorectal cancer","volume":"73","author":"Terme M","year":"2013","journal-title":"J\u00a0Cancer Res"},{"issue":"3","key":"e_1_2_7_22_1","first-page":"iii1","article-title":"Combination of peritumoral administration of CpG\u2010ODN with immunization against VEGF for treatement of malignant glioma","volume":"14","author":"Banissi C","year":"2012","journal-title":"Neuro Oncol"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcas.12724","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.12724","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cas.12724","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.12724","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T08:20:28Z","timestamp":1696234828000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.12724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,29]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["10.1111\/cas.12724"],"URL":"https:\/\/doi.org\/10.1111\/cas.12724","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,29]]}}}